Search results for "RAM"

showing 10 items of 35643 documents

Soil-transmitted helminth infections at very high altitude in Bolivia

2001

A cross-sectional study of soil-transmitted helminthiases in the Northern Bolivian Altiplano was carried out over the 6-year period 1992-97. Prevalences, intensities and associations were analysed from coprological results obtained in 31 surveys (28 in schools and 3 in individuals of all age-groups) performed in 24 Aymara communities located between the city of La Paz and Lake Titicaca, at an altitude of 3800-4200 m. Ascaris lumbricoides and Trichuris trichiura were detected, with local prevalences in the range 1.2-28.0% and 0.0-24.0%, respectively. Significant differences in prevalence rates of trichuriasis were detected, with highest prevalences in male schoolchildren and in subjects aged…

AdultMaleBoliviaVeterinary medicineAdolescentCross-sectional studyTrichuriasisHelminthiasisPrevalenceBiologySoilAge DistributionAltitudeAscariasisPrevalencemedicineHumansSex DistributionChildEggs per gramAgedAltitudePublic Health Environmental and Occupational HealthInfantGeneral MedicineMiddle Agedmedicine.diseasebiology.organism_classificationCross-Sectional StudiesInfectious DiseasesChild PreschoolTrichuris trichiuraFemaleParasitologyAscaris lumbricoidesTransactions of the Royal Society of Tropical Medicine and Hygiene
researchProduct

Herpes Simplex I virus impairs regenerative outcomes of periodontal regenerative therapy in intrabony defects: a pilot study.

2011

Aim To evaluate the impact of herpesvirus type-1 and -2 on the clinical outcomes of periodontal regenerative procedures in isolated deep intrabony pockets, in an experimental population with no detectable periodontal pathogens. Materials and Methods Seventeen periodontal intraosseous defects in 17 moderate-to-advanced periodontitis patients were treated with regenerative therapy and amelogenins. Microbiological evaluation was performed at baseline (after the completion of initial therapy) and at 1 year to exclude the presence of periodontal pathogens. Herpesviruses-1 and -2 DNA were quantified in the pocket tissues associated to the intrabony defect using molecular assays. Clinical attachme…

AdultMaleBone RegenerationCONTROLLED CLINICAL-TRIALHerpesvirus 2 HumanHEALING RESPONSEPopulationAlveolar Bone LossDentistryHerpesvirus 1 HumanACCESS FLAPStatistics NonparametricYoung AdultDental Enamel ProteinsEnamel matrix derivativemedicineAggressive periodontitisHumansPeriodontal PocketGingival RecessionYoung adulteducationBone regenerationGingival recessionGUIDED TISSUE REGENERATIONBONY DEFECTSPeriodontitiseducation.field_of_studybusiness.industryAGGRESSIVE PERIODONTITISMiddle Agedmedicine.diseaseMICROBIOTAHUMAN HERPESVIRUSESPREVALENCEGUIDED TISSUE REGENERATION MINIMALLY INVASIVE SURGICAL TECHNIQUE CONTROLLED CLINICAL-TRIAL AGGRESSIVE PERIODONTITIS HUMAN HERPESVIRUSES HEALING RESPONSE BONY DEFECTS ACCESS FLAP PREVALENCE MICROBIOTAReal-time polymerase chain reactionTreatment OutcomeChronic PeriodontitisDNA ViralGuided Tissue Regeneration PeriodontalPeriodonticsFemaleMINIMALLY INVASIVE SURGICAL TECHNIQUEmedicine.symptombusinessJournal of clinical periodontology
researchProduct

Functional anatomy of motor recovery after early brain damage

2004

Functional magnetic resonance imaging and transcranial magnetic stimulation were used to examine a 34 year-old right-handed patient, who, at the age of 6 years, had experienced sudden right hemiplegia, seizures, and stupor during a bout of measles encephalitis, followed by incomplete distal right motor recovery. Morphological MRI showed massive unilateral enlargement of the left ventricle, associated with extreme thinning of the white and gray matter, with partial preservation of the pyramidal tract. Functional MRI and transcranial magnetic stimulation revealed reorganization of the motor cortices, and integrity of the corticospinal pathway, respectively. Our findings indicate that complete…

AdultMaleCORTEXmedicine.medical_treatmentCHILDHOODAdult; Brain Damage Chronic; Humans; Magnetic Resonance Imaging; Magnetoencephalography; Male; Paresis; Psychomotor Performance; Subacute Sclerosing PanencephalitisCHILDRENBrain damageArts and Humanities (miscellaneous)Magnetic Resonance Imaging; Magnetoencephalography; Paresis; Humans; Brain Damage Chronic; Adult; Psychomotor Performance; Subacute Sclerosing Panencephalitis; MalemedicineHumansBrain DamagePLASTICITYChronicPyramidal tractsmedicine.diagnostic_testSettore M-PSI/02 - Psicobiologia E Psicologia FisiologicaStuporMagnetoencephalographyAnatomymedicine.diseaseMagnetic Resonance ImagingTranscranial magnetic stimulationParesismedicine.anatomical_structureVentricleBrain Damage ChronicMotor recoverySettore MED/26 - NeurologiaNeurology (clinical)Subacute Sclerosing Panencephalitismedicine.symptomFunctional magnetic resonance imagingPsychologyNeuroscienceEncephalitisSTROKEPsychomotor PerformanceMRI
researchProduct

Prevalence of antibodies to human papillomaviruses in the general population of the Czech Republic.

1998

Sera from 450 individuals between the age of 1 and 80 years, representing the general population of the Czech Republic, were tested for the presence of antibodies to human-papillomavirus(HPV)-derived antigens. The following antigens were used: (i) HPV1 virions; (ii) HPV16, -18 and -33-virus-like particles (VLP); (iii) peptides derived from L2 open reading frames (ORFs) of HPV16 and HPV6/11; (iv) peptides derived from HPV16 E2, E4 and E7 ORFs of HPV16. The prevalence of antibodies reactive with the capsid-derived antigens was age-dependent, while no clear age dependence was observed in the distribution of antibodies to peptides derived from HPV16 early proteins. In individual sera, high corr…

AdultMaleCancer ResearchAdolescentvirusesPopulationUterine Cervical NeoplasmsIn Vitro TechniquesAntibodies ViralVirusSerologyOpen Reading FramesAntigenReference ValuesMedicineHumansORFSeducationChildAntigens ViralPapillomaviridaeAgedCzech Republiceducation.field_of_studybiologybusiness.industryAge Factorsvirus diseasesInfantMiddle AgedVirologyOpen reading frameOncologyChild PreschoolImmunologybiology.proteinFemaleViral diseaseAntibodybusinessInternational journal of cancer
researchProduct

Role of ondansetron plus dexamethasone in fractionated chemotherapy.

1993

This randomised, double-blind, parallel-group study was carried out to compare the efficacy and safety profile of ondansetron plus dexamethasone and metoclopramide plus dexamethasone in patients receiving fractionated cisplatin (20-25 mg/m2/day) chemotherapy for the treatment of testicular cancer. An interim analysis of 95 patients showed that the ondansetron regimen was significantly superior compared to the metoclopramide regimen (p0.001). According to the study protocol the study was terminated at this stage. At the time the decision to stop the study was taken, a total of 113 patients had been enrolled and were evaluable on an 'intention to treat' basis. Fifty-six of these had received …

AdultMaleCancer ResearchMetoclopramideAdolescentMetoclopramideVomitingmedicine.medical_treatmentDexamethasoneDrug Administration ScheduleOndansetronTesticular NeoplasmsMedicineHumansIn patientDexamethasoneAgedChemotherapybusiness.industryNauseaGeneral MedicineMiddle AgedOndansetronSafety profileOncologyAnesthesiaCisplatinbusinessmedicine.drugOncology
researchProduct

Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting in…

1995

Background. A single-institution, randomized open trial was prospectively performed to compare orally administered granisetron with or without intramuscularly administered methylprednisolone to metoclopramide plus methylprednisolone in the prevention of delayed nausea and vomiting induced by cisplatin-based chemotherapy. The effects of antiemetic treatments were evaluated from days 2 to 5 of the first cycle after cisplatin administration among patients who had never before received chemotherapy. Methods. All patients were treated with chemotherapeutic regimens containing cisplatin greater than or equal to 80 mg/m 2 and received antiemetic therapy with granisetron 3 mg intravenously for the …

AdultMaleCancer ResearchMetoclopramideNauseamedicine.drug_classMetoclopramideVomitingmedicine.medical_treatmentAdministration OralGranisetronMethylprednisoloneGranisetronNeoplasmsmedicineAntiemeticHumansProspective StudiesAgedChemotherapybusiness.industryNauseaMiddle AgedOncologyMethylprednisoloneAnesthesiaVomitingCorticosteroidAntiemeticsDrug Therapy CombinationFemalemedicine.symptomCisplatinbusinessmedicine.drugCancer
researchProduct

Survival of patients with non-Hodgkin lymphoma in Germany in the early 21st century.

2012

This study provides up-to-date and detailed cancer survival estimates of German patients with non-Hodgkin lymphoma (NHL, International Statistical Classification of Diseases 10th Revision [ICD-10] codes C82-C85) based on data from 11 cancer registries. Period analysis was used to calculate 5-year relative survival in 2002-2006, overall and by gender, age and histology. Comparison was made with patients with NHL in the United States (US) Surveillance, Epidemiology and End Results database in the same time period. Overall 5-year relative survival for patients with NHL in Germany in 2002-2006 was 62.8% and in the US was 65.1%. Survival decreased with age from 81.7% at age 15-49 to 46.5% at age…

AdultMaleCancer Researchmedicine.medical_specialtyAdolescentFollicular lymphomaHistory 21st CenturyYoung AdultOlder patientshemic and lymphatic diseasesInternal medicineGermanyEpidemiologymedicineHumansRegistriesAgedAged 80 and overRelative survivalbusiness.industryLymphoma Non-HodgkinCancerHematologyHistory 20th CenturyMiddle Agedmedicine.diseaseUnited StatesLymphomaOncologyImmunologyPeriod AnalysisHodgkin lymphomaFemalebusinessSEER ProgramLeukemialymphoma
researchProduct

Multicenter phase II study of oral idarubicin in treated and untreated patients with B-chronic lymphocytic leukemia.

2000

Idarubicin is the first anthracycline that can be administered orally facilitating antineoplastic chemotherapy at an improved quality of life. In different studies idarubicin has proved clinical effectiveness in patients with advanced low grade non Hodgkin's lymphoma. We performed a phase II study in 19 patients with untreated and pretreated B-CLL of Binet stage A-C. Idarubucin was administered orally at a dose of 15 mg/m2 over 3 days every 4 weeks. Of 19 evaluable patients (m:f, 16:3, median age 64 years, range 41-80 years) 7 were previously untreated while 12 patients had received prior therapy with fludarabine, chlorambucil or similar non-anthracycline containing regimens. 12 pts had Bin…

AdultMaleCancer Researchmedicine.medical_specialtyAnthracyclineNauseaPhases of clinical researchAdministration OralGastroenterology03 medical and health sciences0302 clinical medicineInternal medicinemedicineIdarubicinHumans030304 developmental biologyAged0303 health sciencesAntibiotics AntineoplasticChlorambucilbusiness.industryHematologyMiddle Agedmedicine.diseaseLeukemia Lymphocytic Chronic B-Cell3. Good healthSurgeryFludarabineOncology030220 oncology & carcinogenesisVomitingFemalemedicine.symptombusinessIdarubicinProgressive diseasemedicine.drugLeukemialymphoma
researchProduct

Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony-stimulating factor.

1989

The in vivo effect of yeast-derived recombinant human granulocyte-macrophage colony-stimulating factor (rh GM-CSF) was investigated in 30 patients with advanced malignancy in a phase Ib trial. Patients were treated at four different dose levels (120 to 1,000 micrograms/m2/d) by either daily intravenous (IV) bolus injection or 24-hour continuous infusion. Administration of rh GM-CSF resulted in a broad spectrum of dose- and schedule-dependent hematopoietic effects. Sustained infusion of rh GM-CSF elicited a maximum 17-fold average peak increase of the total WBC count with mainly neutrophils, eosinophils, and monocytes accounting for this rise, and increases in bone marrow cellularity with a…

AdultMaleCancer Researchmedicine.medical_specialtyMyeloidAdolescentMicrogramMalignancyDrug Administration ScheduleLeukocyte CountColony-Stimulating FactorsIn vivoBone MarrowInternal medicineNeoplasmsmedicineHumansPlateletLeukocytosisGrowth SubstancesInfusions IntravenousAgedbusiness.industryPlatelet CountGranulocyte-Macrophage Colony-Stimulating FactorMiddle Agedmedicine.diseaseRecombinant ProteinsHematopoiesisHaematopoiesisEndocrinologyGranulocyte macrophage colony-stimulating factormedicine.anatomical_structureOncologyImmunologyInjections IntravenousDrug EvaluationFemalemedicine.symptombusinessmedicine.drugJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

Re: Antimicrobial Resistance in More Than 100,000 Escherichia coli Isolates According to Culture Site and Patient Age, Gender, and Location

2011

ABSTRACT Escherichia coli and the antimicrobial pressure exerted on this microorganism can be modulated by factors dependent on the host. In this paper, we describe the distribution of antimicrobial resistance to amikacin, tobramycin, ampicillin, amoxicillin clavulanate, cefuroxime, cefoxitin, cefotaxime, imipenem, ciprofloxacin, fosfomycin, nitrofurantoin, and trimetoprim-sulfametoxazole in more than 100,000 E. coli isolates according to culture site and patient age, gender, and location. Bayesian inference was planned in all statistical analysis, and Markov chain Monte Carlo simulation was employed to estimate the model parameters. Our findings show the existence of a marked difference in…

AdultMaleCefotaximeAdolescentmedicine.drug_classUrologyAntibioticsCefotaximeDrug resistanceFosfomycinBiologymedicine.disease_causeEpidemiology and SurveillanceMicrobiologyYoung AdultAntibiotic resistanceFosfomycinCiprofloxacinPatient ageDrug Resistance Multiple BacterialEscherichia coliHumansMedicinePharmacology (medical)ChildAmikacinEscherichia coliEscherichia coli InfectionsAgedRetrospective StudiesAntibacterial agentAged 80 and overPharmacologybusiness.industryInfantMiddle AgedAntimicrobialAnti-Bacterial AgentsImipenemInfectious DiseasesNitrofurantoinAmikacinChild PreschoolTobramycinAmpicillinFemalebusinessmedicine.drugJournal of Urology
researchProduct